The global market for Biological Drugs was estimated at US$345.3 Billion in 2023 and is projected to reach US$634.4 Billion by 2030, growing at a CAGR of 9.1% from 2023 to 2030. This comprehensive ...

Poland’s poor availability of biological and biosimilar medicines is under the microscope, with policymakers pushing for new accessibility measures to benefit patients in need of advanced therapies.

With patents on originator biologic medicines beginning to expire in the United States, there’s a growing opportunity for biosimilars to enter the market as alternative therapeutic options at ...

The companies will collaborate to create and test circVec DNA–LNP formulations for use in potential therapeutic applications.

Biologics - advanced and complex medicines derived from living organisms such as insulin or monoclonal antibodies - offer more targeted treatments than traditional small molecule drugs ...

Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast ...

President Donald Trump is facing pressure from U.S. hospitals and generic drugmakers to exempt medical goods from his new tariffs on Chinese imports, as they join big pharma lobbyists who have said ...

We believe that our robust clinical trial portfolio provides us with the opportunity to become an industry leader in developing and providing biologic therapeutics for the regenerative medicine ...